IMNN earnings analysis
What we found in IMNN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The available 10-Q excerpt does not include the detailed statements of operations, balance sheet, cash flow statement, segment disclosures, or MD&A needed to assess revenue, margins, liquidity, working capital, and cash-burn trends. Reported Q2 2026 EPS was negative $0.54 based on the supplied earnings information. The filing identifies no material risk-factor changes from the 2025 Form 10-K, while June 2, 2026 secured financing arrangements and ongoing clinical-stage funding needs remain material considerations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Limited equity compensation issuance
- The company issued 49,135 shares of common stock to employees and directors during the quarter ended June 30, 2026 under compensatory arrangements.
- Disclosure controls deemed effective
- Management concluded that disclosure controls were effective at the reasonable assurance level as of June 30, 2026.
- No material control changes
- The filing reports no changes in internal control over financial reporting during the period that materially affected, or were reasonably likely to materially affect, controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Inherent control limitations
- The company states that its disclosure controls and internal controls cannot provide absolute assurance, and that errors, fraud, collusion, or management override may not be detected.
- Ongoing 2025 10-K risk exposure
- The filing incorporates the risks from the 2025 Form 10-K and states there have been no material changes; additional unknown or currently immaterial risks could still adversely affect the business.
- Secured debt financing reliance
- The company has entered into secured financing arrangements dated June 2, 2026, including Secured Promissory Notes A-1 and B, indicating continued reliance on debt financing.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.54
What they said about what is next.
No quantitative revenue or EPS guidance is provided in the available 10-Q text. The filing states that there were no material changes to the risk factors disclosed in the 2025 Form 10-K.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- Imunon, Inc. reported a net loss of $4.3 million for Q1 2026, slightly more than the $4.1 million loss in Q1 2025. With no revenue generated during the quarter, the company's cash position stood at $4.8 million, raising…
- 10-K · March 31, 2026
- Imunon reports compelling Phase II (OVATION 2) clinical results for IMNN-001 showing meaningful overall survival and PFS improvements, while remaining a pre‑revenue clinical-stage company with ongoing Phase 3…
- 10-Q · November 13, 2025
- Imunon reported an improved operating and earnings trend in Q3 2025 with a net loss of $3,429,124 (Q3 EPS $(1.16)) versus a net loss of $4,845,475 (EPS $(3.76)) in Q3 2024, driven by materially lower R&D and overall…
- 10-Q · August 5, 2025
- Imunon reported a materially narrower quarterly loss: net loss of $2,740,559 (EPS $(2.15)) for Q2 2025 versus $4,788,017 (EPS $(7.64)) in Q2 2024, driven by sharply lower operating expenses. Management reduced R&D and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IMNN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever